Evidence Basis
This local Codex synthesis uses the cached Orphanet record for ORPHA:33572 and the PubMed references integrated into the YAML. The Asta retrieval attempt for this disease returned off-topic literature and was not used.
Core Disease Mechanism
- 5-oxoprolinase deficiency maps directly to MONDO:0009825 and ORPHA:33572.
- Orphanet lists OPLAH as the disease-causing gene and records autosomal recessive inheritance.
- OPLAH encodes ATP-dependent 5-oxoprolinase, a gamma-glutamyl-cycle enzyme. Biallelic OPLAH variants reduce 5-oxoprolinase activity and impair clearance of 5-oxo-L-proline, also called pyroglutamic acid.
- The most consistent disease feature is persistent urinary 5-oxoproline elevation, represented in HPO as increased urinary L-pyroglutamic acid.
Clinical Interpretation
- Published molecular reports support a rare biochemical disorder with variable clinical expression. Earlier series described benign or uncertain clinical impact in some families, while later case reports and Orphanet phenotypes include developmental delay, delayed speech, seizures, metabolic acidosis, and brain imaging abnormalities.
- The YAML therefore treats neurologic and metabolic manifestations cautiously: the biochemical phenotype is high-confidence, while clinical penetrance and causality are supported at variable or case-level strength.
YAML Integration Notes
- The primary pathophysiology chain is OPLAH molecular-function deficiency to gamma-glutamyl-cycle block to 5-oxoproline accumulation.
- Genetic evidence uses biallelic OPLAH mutation series and first molecular report evidence.
- Phenotypes are anchored to Orphanet frequency statements and reinforced only where PubMed evidence supports the same clinical or biochemical feature.